PMID- 38056906
OWN - NLM
STAT- Publisher
LR  - 20231206
IS  - 1942-7611 (Electronic)
IS  - 1942-7603 (Linking)
DP  - 2023 Dec 6
TI  - Acute psychotropic, autonomic, and endocrine effects of 
      5,6-methylenedioxy-2-aminoindane (MDAI) compared with 
      3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A 
      self-administration study.
LID - 10.1002/dta.3622 [doi]
AB  - The acute psychoactive, autonomic, and endocrine effects of the new psychoactive 
      substance (NPS) 5,6-methylenedioxy-2-aminoindane (MDAI; 3.0 mg/kg, range 
      180-228 mg) were investigated in six healthy volunteers (four males, two females) 
      in a non-blinded fashion without placebo. Subjective, cardiovascular, and 
      endocrine responses were compared with two different doses of 
      3,4-methylenedioxymethamphetamine (MDMA) (75 mg and 125 mg) described in 
      previously published placebo-controlled studies, which used identical outcome 
      measures including Visual Analogue Scales (VAS), the Adjective Mood Rating Scale 
      (AMRS), and the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale. 
      MDAI was well tolerated and produced subjective effects comparable with those of 
      125 mg MDMA. MDAI increased blood pressure similar to 125 mg MDMA but did not 
      increase heart rate or body temperature. MDAI increased cortisol and prolactin 
      levels and could be detected in serum about 20 min post ingestion and remained 
      detectable at least for 4 days. In urine, MDAI was detectable over a period of at 
      least 6 days. Further clinical investigations are warranted to assess whether 
      MDAI could serve as drug with medicinal properties.
CI  - (c) 2023 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
FAU - Angerer, Verena
AU  - Angerer V
AUID- ORCID: 0000-0002-3081-4609
AD  - Institute of Forensic Medicine, Medical Center - University of Freiburg, Faculty 
      of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Schmid, Yasmin
AU  - Schmid Y
AD  - Psychopharmacology Research, Division of Clinical Pharmacology and Toxicology, 
      Department of Biomedicine and Department of Clinical Research, University 
      Hospital Basel, Basel, Switzerland.
FAU - Franz, Florian
AU  - Franz F
AUID- ORCID: 0000-0001-6158-2882
AD  - Institute of Forensic Medicine, Medical Center - University of Freiburg, Faculty 
      of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Gnann, Heike
AU  - Gnann H
AD  - Research associate, Basel, Switzerland.
FAU - Speer, Jan Manuel
AU  - Speer JM
AD  - Research associate, Basel, Switzerland.
FAU - Gnann, Anke
AU  - Gnann A
AD  - Research associate, Basel, Switzerland.
FAU - Helmecke, Stephan
AU  - Helmecke S
AD  - Research associate, Basel, Switzerland.
FAU - Buchwald, Armin
AU  - Buchwald A
AD  - Institute for Clinical Chemistry and Laboratory Medicine, Medical Center - 
      University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, 
      Germany.
FAU - Brandt, Simon D
AU  - Brandt SD
AUID- ORCID: 0000-0001-8632-5372
AD  - School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, 
      Liverpool, UK.
FAU - Passie, Torsten
AU  - Passie T
AUID- ORCID: 0000-0002-6143-0560
AD  - Hannover Medical School, Hannover, Germany.
AD  - Dr. Senckenberg Institute for History and Ethics in Medicine, Goethe-University 
      Frankfurt/Main, Frankfurt, Germany.
FAU - Liechti, Matthias E
AU  - Liechti ME
AUID- ORCID: 0000-0002-1765-9659
AD  - Psychopharmacology Research, Division of Clinical Pharmacology and Toxicology, 
      Department of Biomedicine and Department of Clinical Research, University 
      Hospital Basel, Basel, Switzerland.
FAU - Auwarter, Volker
AU  - Auwarter V
AUID- ORCID: 0000-0002-1883-2804
AD  - Institute of Forensic Medicine, Medical Center - University of Freiburg, Faculty 
      of Medicine, University of Freiburg, Freiburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20231206
PL  - England
TA  - Drug Test Anal
JT  - Drug testing and analysis
JID - 101483449
SB  - IM
OTO - NOTNLM
OT  - clinical
OT  - entactogens
OT  - new psychoactive substances
OT  - pharmacokinetics
OT  - psychometric
EDAT- 2023/12/07 00:42
MHDA- 2023/12/07 00:42
CRDT- 2023/12/06 20:33
PHST- 2023/11/06 00:00 [revised]
PHST- 2023/08/10 00:00 [received]
PHST- 2023/11/16 00:00 [accepted]
PHST- 2023/12/07 00:42 [medline]
PHST- 2023/12/07 00:42 [pubmed]
PHST- 2023/12/06 20:33 [entrez]
AID - 10.1002/dta.3622 [doi]
PST - aheadofprint
SO  - Drug Test Anal. 2023 Dec 6. doi: 10.1002/dta.3622.